(ČIA) The National Tissue and Cell Center (NCTB) can produce billions of cells fighting COVID-19 without significant investment; one billion cells can serve ca. 20 patients. This was stated in an interview for daily E15 by Michal Zahradníček, the co-owner of PrimeCell, a biotechnology company, which NTCTB is part of. He says that the drug's research cost CZK 150m. The laboratory is now waiting for a statement from the State Institute for Drug Control.